With 50 years of experience and innovation, Daxor manufactures and distributes its patented, FDA-cleared Blood Volume Analysis diagnostic via a rapid, hand-held, lab-based system. The company operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion. In August 2025, Daxor received FDA 510(k) clearance for its patent-pending next-generation rapid, compact, hand-held Blood Volume Analyzer (BVA).
Cyborg Score Rationale
Daxor holds a monopoly-like position in FDA-cleared blood volume measurement with strong clinical validation and expanding adoption across leading hospital systems. Recent FDA clearance for next-generation technology, DoD contracts, and ongoing clinical trials support growth trajectory. Challenges include micro-cap scale, limited revenue visibility, and dependence on hospital adoption rates.
Top Insights
(August 2025) Next-generation BVA received FDA 510(k) clearance with 3x faster processing speed, enabling point-of-care deployment vs. lab-based predecessor
Over 65,000+ blood volume tests performed at leading U.S. hospital centers with demonstrated outcomes in reducing mortality and readmissions in heart failure and critical care
(April 2025) Next-generation device submitted to FDA representing significant technology advancement in diagnostic speed and portability
Strategic partnerships with leading academic medical centers (Duke, Cleveland Clinic) and U.S. Department of Veterans Affairs; development contract with DoD for combat casualty care applications
Named Competitors
EV1000 — Hemodynamic monitoring and fluid management guidance
Sonosite Ultrasound — Point-of-care ultrasound for clinical assessment
Recent Developments
(August 2025) FDA 510(k) clearance for next-generation rapid, compact Blood Volume Analyzer
(April 2025) Submission of next-generation BVA to FDA for clearance
(May 2023) Completed $4.0 million underwritten public offering at $9.75 per share
Open the full interactive Daxor Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.